Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

GNI Group Gelecekteki Büyüme

Future kriter kontrolleri 4/6

GNI Group kazanç ve gelirin sırasıyla yıllık 18.9% ve 24.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 20.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.9%

Kazanç büyüme oranı

20.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	10.0%
Gelir büyüme oranı	24.6%
Gelecekteki özkaynak getirisi	15.9%
Analist kapsamı	Low
Son güncelleme	12 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar

Sep 20

GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution

Aug 27

GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 06

Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)

Jun 20

Is GNI Group (TSE:2160) Using Too Much Debt?

Apr 12

News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts

Mar 19

Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce

Feb 28

Kazanç ve Gelir Büyüme Tahminleri

TSE:2160 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	57,916	14,071	10,641	11,312	3
12/31/2025	49,391	13,722	9,135	9,257	3
12/31/2024	34,966	9,673	4,105	6,088	3
6/30/2024	23,647	6,766	2,443	4,210	N/A
3/31/2024	27,752	9,550	3,581	5,490	N/A
12/31/2023	26,010	8,094	4,474	6,549	N/A
9/30/2023	25,204	1,525	2,488	4,997	N/A
6/30/2023	23,360	1,370	-1,540	876	N/A
3/31/2023	17,691	35	-1,429	677	N/A
12/31/2022	17,418	388	-1,546	393	N/A
9/30/2022	15,915	848	-1,756	-365	N/A
6/30/2022	14,379	801	-1,219	-159	N/A
3/31/2022	12,751	985	-1,448	-530	N/A
12/31/2021	12,690	1,066	-141	552	N/A
9/30/2021	12,356	2,086	218	883	N/A
6/30/2021	11,858	1,955	1,318	1,669	N/A
3/31/2021	11,520	1,558	1,986	2,333	N/A
12/31/2020	9,773	1,258	1,020	1,377	N/A
9/30/2020	9,066	367	1,098	1,530	N/A
6/30/2020	8,407	247	691	1,289	N/A
3/31/2020	7,996	194	686	1,254	N/A
12/31/2019	7,446	181	176	788	N/A
9/30/2019	6,734	147	308	926	N/A
6/30/2019	6,279	154	86	789	N/A
3/31/2019	5,581	258	-398	412	N/A
12/31/2018	5,018	-200	-224	621	N/A
9/30/2018	4,802	47	-477	180	N/A
6/30/2018	4,095	-130	-728	-116	N/A
3/31/2018	3,310	-337	N/A	-144	N/A
12/31/2017	2,648	-175	N/A	-476	N/A
9/30/2017	1,939	-97	N/A	-470	N/A
6/30/2017	1,473	-111	N/A	-284	N/A
3/31/2017	1,347	-406	N/A	-327	N/A
12/31/2016	1,306	-513	N/A	-518	N/A
9/30/2016	1,117	-858	N/A	N/A	N/A
6/30/2016	1,073	-956	N/A	-514	N/A
3/31/2016	1,093	-752	N/A	N/A	N/A
12/31/2015	1,016	-623	N/A	-382	N/A
9/30/2015	928	-440	N/A	N/A	N/A
6/30/2015	814	-360	N/A	-574	N/A
3/31/2015	651	-345	N/A	N/A	N/A
12/31/2014	474	-327	N/A	-567	N/A
9/30/2014	334	-527	N/A	N/A	N/A
6/30/2014	254	-787	N/A	-862	N/A
3/31/2014	202	-769	N/A	N/A	N/A
12/31/2013	183	-730	N/A	-662	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2160 'nin tahmini kazanç büyümesi (yıllık 18.9% ) tasarruf oranının ( 0.3% ) üzerindedir.

Kazançlar ve Piyasa: 2160 şirketinin kazançlarının (yıllık 18.9% ) JP pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 2160 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 2160 şirketinin gelirinin (yıllık 24.6% ) JP pazarından (yıllık 4.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 2160 şirketinin gelirinin (yıllık 24.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2160 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.9 %).

GNI Group Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 38%

Consensus EPS estimates fall by 47%

GNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year 2022

GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2022

Consensus forecasts updated

GNI Group Ltd. Provides Earnings Guidance for the Year December 31, 2022

Recent updates

GNI Group Ltd. to Report Q3, 2024 Results on Nov 14, 2024

After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar

Investor sentiment improves as stock rises 19%

GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: JP¥3.31 (vs JP¥34.98 in 2Q 2023)

Investor sentiment deteriorates as stock falls 24%

GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)

GNI Group Ltd. to Report Q2, 2024 Results on Aug 14, 2024

High number of new directors

Is GNI Group (TSE:2160) Using Too Much Debt?

GNI Group Ltd. to Report Q1, 2024 Results on May 15, 2024

News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts

Consensus revenue estimates increase by 38%

Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce

Investor sentiment improves as stock rises 43%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GNI Group Ltd., Annual General Meeting, Mar 28, 2024

New minor risk - Shareholder dilution

GNI Group Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: EPS: JP¥11.67 (vs JP¥8.40 in 3Q 2022)

GNI Group Ltd. Announces New Management Structure

Investor sentiment improves as stock rises 44%

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: JP¥34.96 (vs JP¥6.85 in 2Q 2022)

Consensus EPS estimates fall by 47%

Gni Group Ltd. Announces Notice of Executive Officer Appointment

New major risk - Share price stability

First quarter 2023 earnings released: JP¥0.042 loss per share (vs JP¥7.40 profit in 1Q 2022)

Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China

Less than half of directors are independent

Full year 2022 earnings released: EPS: JP¥9.61 (vs JP¥22.72 in FY 2021)

GNI Group Ltd. to Report Fiscal Year 2022 Final Results on Mar 31, 2023

GNI Group Ltd., Annual General Meeting, Mar 30, 2023

Investor sentiment improved over the past week

GNI Group Ltd. Appoints of Kazuhiro Kawauchi as Chief Business Development Officer, Effective from January 1, 2023

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

GNI Group Ltd. to Report Fiscal Year 2022 Results on Feb 15, 2023

EP Mediate Co., Ltd. signed an agreement to acquire 60% stake in Micren Healthcare Co., Ltd.

Third quarter 2022 earnings released: EPS: JP¥8.42 (vs JP¥7.42 in 3Q 2021)

GNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS: JP¥6.85 (vs JP¥10.76 in 2Q 2021)

GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Investor sentiment improved over the past week

GNI Group Ltd. Provides Earnings Guidance for the Year December 31, 2022

Price target decreased to JP¥2,100

GNI Group Ltd. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

GNI Group Ltd. Announces Board Changes

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

GNI Group Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

GNI Group Ltd., Annual General Meeting, Mar 25, 2022

GNI Group Ltd. Announces F351 Phase III Clinical Trial Roadmap in China

GNI Group Ltd. Announces F351 Phase III Clinical Trial Roadmap in China

Investor sentiment deteriorated over the past week

GNI Group Ltd. Announces First Dosing of F573 Phase I Clinical Trial in China

GNI Group Ltd. Announces First Patient Enrollment of F351 Phase III Clinical Trial in China

Third quarter 2021 earnings released: EPS JP¥7.44 (vs JP¥5.11 in 3Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS JP¥28.96 (vs JP¥4.28 in FY 2019)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS JP¥25.05 (vs JP¥4.28 in FY 2019)

GNI Group Ltd. announced that it expects to receive ¥86.42546 million in funding from CVI Investments, Inc.